JP2010502767A5 - - Google Patents

Download PDF

Info

Publication number
JP2010502767A5
JP2010502767A5 JP2009538434A JP2009538434A JP2010502767A5 JP 2010502767 A5 JP2010502767 A5 JP 2010502767A5 JP 2009538434 A JP2009538434 A JP 2009538434A JP 2009538434 A JP2009538434 A JP 2009538434A JP 2010502767 A5 JP2010502767 A5 JP 2010502767A5
Authority
JP
Japan
Prior art keywords
salt
compound
medicament
compound according
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009538434A
Other languages
English (en)
Japanese (ja)
Other versions
JP5161237B2 (ja
JP2010502767A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/078103 external-priority patent/WO2008033798A2/en
Publication of JP2010502767A publication Critical patent/JP2010502767A/ja
Publication of JP2010502767A5 publication Critical patent/JP2010502767A5/ja
Application granted granted Critical
Publication of JP5161237B2 publication Critical patent/JP5161237B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009538434A 2006-09-11 2007-09-11 Ｓｙｋキナーゼ阻害剤としてのピロロピラジン Expired - Fee Related JP5161237B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82516806P 2006-09-11 2006-09-11
US60/825,168 2006-09-11
PCT/US2007/078103 WO2008033798A2 (en) 2006-09-11 2007-09-11 A pyrrolopyrazin as syk-kinase inhibitor

Publications (3)

Publication Number Publication Date
JP2010502767A JP2010502767A (ja) 2010-01-28
JP2010502767A5 true JP2010502767A5 (OSRAM) 2010-10-07
JP5161237B2 JP5161237B2 (ja) 2013-03-13

Family

ID=39032357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009538434A Expired - Fee Related JP5161237B2 (ja) 2006-09-11 2007-09-11 Ｓｙｋキナーゼ阻害剤としてのピロロピラジン

Country Status (32)

Country Link
US (2) US8658649B2 (OSRAM)
EP (1) EP2094708B1 (OSRAM)
JP (1) JP5161237B2 (OSRAM)
KR (1) KR101443056B1 (OSRAM)
CN (2) CN103804383A (OSRAM)
AR (1) AR062745A1 (OSRAM)
AU (1) AU2007296592B8 (OSRAM)
BR (1) BRPI0716781A2 (OSRAM)
CA (1) CA2663175C (OSRAM)
CL (1) CL2007002617A1 (OSRAM)
CO (1) CO6160236A2 (OSRAM)
CR (1) CR10636A (OSRAM)
DK (1) DK2094708T3 (OSRAM)
ES (1) ES2437318T3 (OSRAM)
GT (1) GT200900055A (OSRAM)
HN (1) HN2009000455A (OSRAM)
IL (1) IL197381A (OSRAM)
MA (1) MA30781B1 (OSRAM)
MX (1) MX2009002616A (OSRAM)
MY (1) MY148107A (OSRAM)
NI (1) NI200900021A (OSRAM)
NO (1) NO20091265L (OSRAM)
NZ (1) NZ575496A (OSRAM)
PE (1) PE20081372A1 (OSRAM)
PT (1) PT2094708E (OSRAM)
RU (1) RU2440352C2 (OSRAM)
TN (2) TN2009000049A1 (OSRAM)
TW (1) TWI399379B (OSRAM)
UA (1) UA94622C2 (OSRAM)
UY (1) UY30584A1 (OSRAM)
WO (1) WO2008033798A2 (OSRAM)
ZA (1) ZA200901073B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE519763T1 (de) 2008-02-25 2011-08-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
CN101952295B (zh) 2008-02-25 2013-11-20 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
CN101945877B (zh) 2008-02-25 2013-07-03 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
PT2250172E (pt) 2008-02-25 2011-11-30 Hoffmann La Roche Inibidores de pirrolpirazina-cinase
CN101939324B (zh) 2008-02-25 2014-10-15 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
CA2717991A1 (en) * 2008-03-10 2009-09-17 Sanofi-Aventis Treatment for ocular-related disorders
FR2929851B1 (fr) 2008-04-09 2012-11-30 Centre Nat Rech Scient Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
AR074437A1 (es) 2008-12-03 2011-01-19 Sanofi Aventis Tratamiento para la glomerulonefritis
MX2011004793A (es) * 2008-12-04 2011-05-30 Sanofi Aventis Formas cristalinas.
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
US20110112101A1 (en) * 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders
AR075869A1 (es) * 2009-03-19 2011-05-04 Sanofi Aventis Sintesis de azaindoles
KR101790255B1 (ko) 2009-12-23 2017-10-26 다케다 야쿠힌 고교 가부시키가이샤 Ｓｙｋ 억제제로서의 융합된 헤테로방향족 피롤리디논
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8481541B2 (en) * 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
RU2012152352A (ru) * 2010-05-20 2014-06-27 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-b]ПИРАЗИН-7-КАРБОКСАМИДА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ JAK И SYK
EP2571881A1 (en) 2010-05-20 2013-03-27 F.Hoffmann-La Roche Ag Pyrrolopyrazine derivatives as syk and jak inhibitors
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
BR112015002262A2 (pt) * 2012-08-21 2019-12-10 Hoffmann La Roche compostos, métodos para os tratamentos de uma condição inflamatória, artrite reumatóide, asma e distúrbio imunológico; composição farmacêutica, utilização do composto e invenção
SG11201600373YA (en) * 2013-07-31 2016-02-26 Gilead Sciences Inc Syk inhibitors
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN116969927B (zh) * 2023-06-07 2024-03-19 中南民族大学 一种从荜茇中提取分离的化合物及该化合物在制备抗炎药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1141949A (en) 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
US3992392A (en) 1973-04-27 1976-11-16 The Ohio State University Research Foundation Synthesis of indoles from anilines and intermediates therein
SE9100920D0 (sv) 1991-03-27 1991-03-27 Astra Ab New active compounds
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
WO1995033748A1 (en) 1994-06-09 1995-12-14 Smithkline Beecham Corporation Endothelin receptor antagonists
FR2732969B1 (fr) 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK0948495T3 (da) 1996-11-19 2004-06-01 Amgen Inc Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler
US6312835B1 (en) 1997-02-13 2001-11-06 Queen's University At Kingston Luminescent compounds and methods of making and using same
CA2283961A1 (en) 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
WO1998047899A1 (en) 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
ES2241146T3 (es) 1997-08-05 2005-10-16 Pfizer Products Inc. 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido y.
PL340412A1 (en) 1997-10-20 2001-01-29 Hoffmann La Roche Bicyclic kinase inhibitors
ES2401070T3 (es) 1998-03-06 2013-04-16 Metabasis Therapeutics, Inc. Nuevos profármacos para compuestos que contienen fósforo
WO1999051596A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP1067931A1 (en) 1998-04-02 2001-01-17 Merck & Co., Inc. (a New Jersey corp.) Antagonists of gonadotropin releasing hormone
ATE482945T1 (de) 1998-05-26 2010-10-15 Chugai Pharmaceutical Co Ltd Heterozyklische indolderivate und mono- oder diazaindol-derivate
SK3852001A3 (en) 1998-09-18 2003-03-04 Basf Ag 4-Aminopyrrolopyrimidines as kinase inhibitors
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
IL150388A0 (en) * 1999-12-24 2002-12-01 Aventis Pharma Ltd Azaindoles
GB9930698D0 (en) * 1999-12-24 2000-02-16 Rhone Poulenc Rorer Ltd Chemical compounds
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
DE10009000A1 (de) 2000-02-25 2001-08-30 Basf Ag Verfahren zur Herstellung substituierter Indole
CA2402516A1 (en) 2000-03-20 2001-09-27 Roopa Rai Non-amidine containing protease inhibitors
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US6673923B2 (en) 2000-05-03 2004-01-06 Tularik Inc. Pyrazole antimicrobial agents
MXPA02010763A (es) 2000-06-14 2003-03-10 Warner Lambert Co Heterociclicos biciclos-6,5 fusionados.
CA2424222A1 (en) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
IL161576A0 (en) 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
US20040082365A1 (en) * 2002-07-18 2004-04-29 Celerica Ltd Digitization and transmitting cellular RF signals by several light wavelengths
EP1388541A1 (en) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
EP1778687A2 (en) * 2004-07-27 2007-05-02 SGX Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
FR2876582B1 (fr) 2004-10-15 2007-01-05 Centre Nat Rech Scient Cnrse Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
WO2006052712A1 (en) 2004-11-08 2006-05-18 Baxter International Inc. Nanoparticulate compositions of tubulin inhibitor
NZ555566A (en) * 2004-11-22 2009-12-24 Vertex Pharma Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
US20110112101A1 (en) 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders

Similar Documents

Publication Publication Date Title
JP2010502767A5 (OSRAM)
CA2663175A1 (en) Kinase inhibitor
JP6194389B2 (ja) キナーゼ調節のための化合物および方法、ならびにその適応
KR101663339B1 (ko) Ｒａｆ 키나제의 억제를 위한 피롤로［２,３-ｂ］피리딘 유도체
JP2010526814A5 (OSRAM)
JP2010515715A5 (OSRAM)
JP2009516653A5 (OSRAM)
JP2009502743A5 (OSRAM)
JP2010509356A5 (OSRAM)
JP2010504344A5 (OSRAM)
JP2017506250A5 (OSRAM)
JP2016503779A5 (OSRAM)
JP2016014037A (ja) 縮合複素環式化合物およびそれらの使用
JP2012526766A5 (OSRAM)
TW201022281A (en) Imidazolothiazole compounds and methods of use thereof
JP2008518904A5 (OSRAM)
JP2008513498A5 (OSRAM)
JP2006514012A5 (OSRAM)
JP2014065696A5 (OSRAM)
TW201443043A (zh) 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
JP2009543843A (ja) 直接トロンビン阻害剤に関する新規適応
JP2017505293A5 (OSRAM)
JP2009506014A5 (OSRAM)
JP2016534124A5 (OSRAM)
JP2010505961A5 (OSRAM)